F.H.J. van den Hoogen

TL;DR: The anti-CCP ELISA might be very useful for diagnostic and therapeutic strategies in RA of recent onset and appears to be highly specific for RA, using prevalent RA and non-RA sera.

TL;DR: It is shown that autoantibodies reactive with synthetic peptides containing the unusual amino acid citrulline, a posttranslationally modified arginine residue, are specifically present in the sera of RA patients, and the presence of these antibodies early in disease, even before other disease manifestations occur, are indicative for a possible role of citrulling epitopes in the pathogenesis of RA.

TL;DR: The data show that in almost 70% of RA patients, anti-CCP antibody is present at the early stages of disease, and patients with anti- CCP-positive patients developed significantly more severe radiologic damage than patients who were anti- CCP negative.

TL;DR: Evidence-based, consensus-derived recommendations for the treatment of systemic sclerosis are useful for rheumatologists to help guide treatment for patients with SSc and may also help to define directions for future clinical research in SSc.

TL;DR: Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased treatment-related mortality in the first year after treatment, however, HCST conferred a significant long-term event-free survival benefit.